Opendata, web and dolomites

FGFSTAB

Industrial Production of Stable Fibroblast Growth Factors for Regenerative Medicine and Related Research Areas

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FGFSTAB project word cloud

Explore the words cloud of the FGFSTAB project. It provides you a very rough idea of what is the project "FGFSTAB" about.

demanding    minutes    diabetes    lower    technological    stability    fgf    ageing    authorization    world    see    stable    risk    cleared    fireprot    innovative    chronic    trials    effectiveness    goes    hours    organisms    fgfs    natural    administrations    started    incidences    half    healing    tissue    slow    optimization    population    skin    safe    biotechnological    aging    industrial    poor    fgfstab    regenerative    life    fact    frequent    homeostasis    treatment    stress    therapy    enantis    financial    proteins    investing    circulation    limited    ulcers    expertise    practise    companies    marketing    medicine    fibroblast    surgical    commercial    rising    heavily    body    primarily    instrument    market    platform    adverse    obesity    despite    dressings    closes    play    engineering    care    additional    sme    protein    angiogenesis    embryonic    good    close    wound    necessitating    proprietary    greatest    global    trauma    course    clinical    thermal    manufacturing    gap   

Project "FGFSTAB" data sheet

The following table provides information about the project.

Coordinator
ENANTIS SRO 

Organization address
address: KAMENICE 771/34
city: BRNO
postcode: 625 00
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Czech Republic [CZ]
 Project website https://www.enantis.com/fgfstab/
 Total cost 1˙030˙000 €
 EC max contribution 1˙030˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ENANTIS SRO CZ (BRNO) coordinator 1˙030˙000.00

Map

 Project objective

The FGFSTAB project closes the gap between Enantis knowledge and expertise on protein engineering and the commercial applications of stable fibroblast growth factors (FGFs). FGFs are essential to the embryonic development, maintain tissue homeostasis, may slow down ageing of the organisms, and primarily promote angiogenesis and wound healing. FGFs see the greatest application in the care and treatment of chronic skin ulcers, but find use also in surgical and trauma wound healing. The global wound care market is rapidly growing due to the rising aging population and growing incidences of obesity and diabetes. Advanced wound dressings, such as those involving growth factors, play an important role in current regenerative medicine and companies around the world have started investing heavily in research and development of growth factor-based products. However, despite clinical value, applications of FGFs are limited by the fact that natural proteins have poor thermal stability and a short half-life in the circulation; they are often cleared from the body within hours, if not minutes, thus necessitating frequent administrations during the course of treatment, which goes hand in hand with a higher risk of adverse effects and lower cost-effectiveness of the protein therapy. The key objective of the FGFSTAB project is to use an innovative technological platform, based on the application of Enantis proprietary protein optimization concept FireProt, to increase FGF stability under various stress conditions. Additional challenges including high cost of production, current Good Manufacturing Practise, development of delivery systems for safe and effective wound healing, and pre-clinical testing to support future clinical trials and marketing authorization, will be targeted as well. Financial support provided within SME Instrument phase 2 will help us to close the gap from demanding biotechnological development to the target industrial application in regenerative medicine.

 Deliverables

List of deliverables.
FGFSTAB web presentation Websites, patent fillings, videos etc. 2019-09-09 15:23:38

Take a look to the deliverables list in detail:  detailed list of FGFSTAB deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FGFSTAB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FGFSTAB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More